当前位置:白金会官网 > 所有分类 > 医药卫生 > 临床医学 > 2015ASCO淋巴瘤靶向治疗进展-林桐榆
免费下载此文档侵权投诉

2015ASCO淋巴瘤靶向治疗进展-林桐榆

启示与创新:将数据转换为知识

2014 FDA批准的肿瘤靶向药物(4+3/9) Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014 Zykadia (ceritinib); Novartis; For the treatment of ALK+ metastatic nonsmall cell lung cancer, Approved April 2014 Cyramza (ramucirumab); Eli Lilly; For the treatment of gastric cancer, Approved April 2014 Zydelig (idelalisib); Gilead; For the treatment of relapsed CLL, follicular Bcell NHL and small lymphocytic lymphoma, Approved July 2014 Beleodaq (belinostat); Spectrum Pharmaceuticals; For the treatment of relapsed or refractory peripheral T-cell lymphoma, Approved July 2014 Keytruda (pembrolizumab); Merck; For the treatment of unresectable or metastatic melanoma, Approved September 2014 Blincyto (blinatumomab); Amgen; For the treatment of Philadelphia chromosome-negative relapsed/refractory B cell precursor acute lymphoblastic leukemia, Approved December 2014 Lynparza (olaparib); AstraZeneca; For the treatment of previously treated BRCA mutated advanced ovarian cancer, Approved December 2014 Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of unresectable or metastatic melanoma, Approved December 2014

2015年ASCO淋巴瘤靶向治疗进展 中山大学肿瘤防治中心林桐榆 2015. 8

2015年 ASCO会议淋巴瘤靶向治疗的主要进展 Obinutuzumab联合苯达莫斯汀对比苯达莫斯汀单药治疗对利妥昔单抗耐药的惰性非霍奇金淋巴瘤

Obinutuzumab联合苯达莫斯汀对比苯达莫斯汀单药治疗对利妥昔单抗耐药的惰性非霍奇金淋巴瘤: III期 GADOLIN研究的初步结果 L.H.Sehn et al, 2015 ASCO 8502

Obinutuzumab(GA101)在 NHL Obinutumab是糖基化 II型CD20单抗,在前期I期复发难治NHL研究中显示出疗效

抗CD20单抗联合化疗显著提高PFS, Obinutuzumab优于 Rituximab

增加直接细胞死亡及较I型单抗能减少补体活化

Obinutuzumab联合化疗显著提高 PFS HR 0.18; 95% CI, 0.13 -0.24; P<0.001

Obinutuzumab联合化疗显著优于 Rituximab HR 0.39; 95% CI, 0.31 -0.49; P<0.001

Obinutumab联合苯达莫斯汀较利妥昔单抗联合苯达莫斯汀在异种移植淋巴瘤模型显示出更好的疗效 3.

糖基化能增强 FcyRIIIa/b的亲和力及增强相对于I型单抗ADCC及ADCP能力 1. Mossner E et al;; Blood 2010,115;4393-402; 2. Golay J, et al. Blood 2013;122.3482-91; Niederfellner G, et al. Blood 2011;118, 358-67 4. Ferrara C, et al.PNAS 2011;108:12669-74 5. Sehn LH, et al. Blood 2012;119-5118-25 6. Sales G, et al. Blood2012;119:5126-32 Herting F et al. Leuk Lymphoma 2014;55:2151-60

26.7个月 11.1个月 15.2个月

26.7个月

7.

Goede V, et al. N Engl J Med. 2014 Mar 20;370(12):1101-10.

2015ASCO淋巴瘤靶向治疗进展-林桐榆

第1页

免费下载Word文档免费下载:2015ASCO淋巴瘤靶向治疗进展-林桐榆

(下载1-15页,共15页)

我要评论

返回顶部